BACKGROUND AND OBJECTIVE: Valproic acid (VPA) follows a non-linear pharmacokinetic profile in terms of protein-binding saturation. The total daily dose regarding VPA clearance is a simple power function, which may partially explain the non-linearity of the pharmacokinetic profile; however, it may be confounded by the therapeutic drug monitoring effect. The aim of this study was to develop a population pharmacokinetic model for VPA based on protein-binding saturation in pediatric patients with epilepsy. METHODS: A total of 1,107 VPA serum trough concentrations at steady state were collected from 902 epileptic pediatric patients aged from 3 weeks to 14 years at three hospitals. The population pharmacokinetic model was developed using NONMEM(®) software. The ability of three candidate models (the simple power exponent model, the dose-dependent maximum effect [DDE] model, and the protein-binding model) to describe the non-linear pharmacokinetic profile of VPA was investigated, and potential covariates were screened using a stepwise approach. Bootstrap, normalized prediction distribution errors and external evaluations from two independent studies were performed to determine the stability and predictive performance of the candidate models. RESULTS: The age-dependent exponent model described the effects of body weight and age on the clearance well. Co-medication with carbamazepine was identified as a significant covariate. The DDE model best fitted the aim of this study, although there were no obvious differences in the predictive performances. The condition number was less than 500, and the precision of the parameter estimates was less than 30 %, indicating stability and validity of the final model. CONCLUSION: The DDE model successfully described the non-linear pharmacokinetics of VPA. Furthermore, the proposed population pharmacokinetic model of VPA can be used to design rational dosage regimens to achieve desirable serum concentrations.
BACKGROUND AND OBJECTIVE:Valproic acid (VPA) follows a non-linear pharmacokinetic profile in terms of protein-binding saturation. The total daily dose regarding VPA clearance is a simple power function, which may partially explain the non-linearity of the pharmacokinetic profile; however, it may be confounded by the therapeutic drug monitoring effect. The aim of this study was to develop a population pharmacokinetic model for VPA based on protein-binding saturation in pediatric patients with epilepsy. METHODS: A total of 1,107 VPA serum trough concentrations at steady state were collected from 902 epileptic pediatric patients aged from 3 weeks to 14 years at three hospitals. The population pharmacokinetic model was developed using NONMEM(®) software. The ability of three candidate models (the simple power exponent model, the dose-dependent maximum effect [DDE] model, and the protein-binding model) to describe the non-linear pharmacokinetic profile of VPA was investigated, and potential covariates were screened using a stepwise approach. Bootstrap, normalized prediction distribution errors and external evaluations from two independent studies were performed to determine the stability and predictive performance of the candidate models. RESULTS: The age-dependent exponent model described the effects of body weight and age on the clearance well. Co-medication with carbamazepine was identified as a significant covariate. The DDE model best fitted the aim of this study, although there were no obvious differences in the predictive performances. The condition number was less than 500, and the precision of the parameter estimates was less than 30 %, indicating stability and validity of the final model. CONCLUSION: The DDE model successfully described the non-linear pharmacokinetics of VPA. Furthermore, the proposed population pharmacokinetic model of VPA can be used to design rational dosage regimens to achieve desirable serum concentrations.
Authors: Ron J Keizer; Michel van Benten; Jos H Beijnen; Jan H M Schellens; Alwin D R Huitema Journal: Comput Methods Programs Biomed Date: 2010-06-02 Impact factor: 5.428
Authors: B Blanco-Serrano; M J Otero; D Santos-Buelga; M J García-Sánchez; J Serrano; A Domínguez-Gil Journal: Biopharm Drug Dispos Date: 1999-07 Impact factor: 1.627
Authors: Christine E Staatz; Stephen B Duffull; Bryce Kiberd; Albert D Fraser; Susan E Tett Journal: Eur J Clin Pharmacol Date: 2005-07-28 Impact factor: 2.953
Authors: Brian J Anderson; Karel Allegaert; John N Van den Anker; Veerle Cossey; Nicholas H G Holford Journal: Br J Clin Pharmacol Date: 2006-07-21 Impact factor: 4.335
Authors: S Ueshima; T Aiba; T Makita; S Nishihara; Y Kitamura; Y Kurosaki; H Kawasaki; T Sendo; Y Ohtsuka; Y Gomita Journal: J Clin Pharm Ther Date: 2008-02 Impact factor: 2.512
Authors: Nathan T James; Joseph H Breeyear; Richard Caprioli; Todd Edwards; Brian Hachey; Prince J Kannankeril; Jacob M Keaton; Matthew D Marshall; Sara L Van Driest; Leena Choi Journal: Br J Clin Pharmacol Date: 2022-01-28 Impact factor: 3.716